Malaria Clinical Trial
Official title:
Randomized, Double-Blind, Placebo-Controlled, Regimen Optimization Study of a Radiation-Attenuated Plasmodium Falciparum (Pf) Sporozoite Vaccine (PfSPZ Vaccine) in Equatoguinean Adults
This is a phase 1, randomized regimen optimization study of PfSPZ Vaccine in healthy Equatoguinean volunteers to determine if a condensed, rapid immunization regimen is safe and efficacious. Four different regimens 4 weeks or less in duration will be evaluated for safety, tolerability, immunogenicity, and protective efficacy in comparison to a gold standard 16-week regimen.
This double-blind, placebo-controlled clinical trial will be conducted in 104 Equatoguinean
healthy men and women 18-45 years of age divided into four groups of 26 subjects receiving
one of four dosing regimens. The study is designed to test the hypothesis that 2 or 4 doses
of 9x10^5 PfSPZ of PfSPZ Vaccine administered by direct venous inoculation (DVI) over 6-7
days as the priming immunization, with or without a boosting immunization at 4 or 16 weeks
after the last priming dose, will (1) be safe and well tolerated; and (2) induce immunity
leading to protection against homologous controlled human malaria infection (CHMI) performed
at 8 weeks after the final immunization by DVI injection of PfSPZ Challenge. The first
regimen will test the radiation-attenuated whole sporozoite PfSPZ Vaccine in a dose of
9.0x10^5 administered by DVI with four priming immunizations followed by a boost after 16
weeks. The second regimen will follow the same dosing and administering schedule, but without
the boost after 16 weeks to study if a boost may be necessary. The third regimen will follow
the first regimen with the interval duration to the boost shortened to only 4 weeks. In the
fourth and final regimen, the vaccine will be administered two times instead of four followed
by a boost in 4 weeks to evaluate if two priming immunizations will be sufficient to confer
protection. In summary:
- Group 1: 21 subjects will receive 9.0x10^5 PfPSZ and 5 subjects will receive normal
saline (NS) placebo on Days 1, 3, 5, 7, and 113.
- Group 2: 21 subjects will receive 9.0x10^5 PfPSZ and 5 subjects will receive NS on Days
1, 3, 5, and 7.
- Group 3: 21 subjects will receive 9.0x10^5 PfPSZ and 5 subjects will receive NS on Days
1, 3, 5, 7, and 29.
- Group 4: 21 subjects will receive 9.0x10^5 PfPSZ and 5 subjects will receive NS on Days
1 and 8.
The safety and tolerability of each regimen will be measured by recording (1) solicited and
unsolicited adverse events, (2) immunogenicity by assessing humoral and cellular immune
responses pre- and post-vaccination, and (3) vaccine efficacy (VE) by measuring protection
against homologous CHMI administered by DVI of PfSPZ Challenge (NF54) at 8 weeks post-final
vaccination.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
Completed |
NCT02315690 -
Evaluation of Reactive Focal Mass Drug Administration for Malaria Elimination in Swaziland
|
Phase 3 |